These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 33559417)

  • 1. How to start niraparib in real-world Asian ovarian cancer patients?
    Hong SH
    J Gynecol Oncol; 2021 Mar; 32(2):e36. PubMed ID: 33559417
    [No Abstract]   [Full Text] [Related]  

  • 2. Real-world Experience of Niraparib in Newly-diagnosed Epithelial Ovarian Cancer.
    Shin W; Noh JJ; Baek SH; Kim BG; Lim MC; Park SY
    Anticancer Res; 2021 Sep; 41(9):4603-4607. PubMed ID: 34475088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trial.
    Mirza MR; Benigno B; Dørum A; Mahner S; Bessette P; Barceló IB; Berton-Rigaud D; Ledermann JA; Rimel BJ; Herrstedt J; Lau S; du Bois A; Herráez AC; Kalbacher E; Buscema J; Lorusso D; Vergote I; Levy T; Wang P; de Jong FA; Gupta D; Matulonis UA
    Gynecol Oncol; 2020 Nov; 159(2):442-448. PubMed ID: 32981695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.
    Moore KN; Secord AA; Geller MA; Miller DS; Cloven N; Fleming GF; Wahner Hendrickson AE; Azodi M; DiSilvestro P; Oza AM; Cristea M; Berek JS; Chan JK; Rimel BJ; Matei DE; Li Y; Sun K; Luptakova K; Matulonis UA; Monk BJ
    Lancet Oncol; 2019 May; 20(5):636-648. PubMed ID: 30948273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Niraparib for the Treatment of Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.
    Kerliu L; Myruski S; Bhatti A; Soni P; Petrosius P; Pervanas HC; Horton ER
    Ann Pharmacother; 2020 Oct; 54(10):1010-1015. PubMed ID: 32172572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Addendum: A phase II trial of cytoreductive surgery combined with niraparib maintenance in platinum-sensitive, secondary recurrent ovarian cancer: SGOG SOC-3 study.
    Shi T; Xiang L; Zhu J; Liu J; Zhang P; Wang H; Feng Y; Zhu T; Zhang Y; Yu A; Jiang W; Wang X; Zhu Y; Wu S; Teng Y; Zhang J; Jiang R; Zhang W; Jia H; Zang R
    J Gynecol Oncol; 2022 Jul; 33(4):e63. PubMed ID: 35775688
    [No Abstract]   [Full Text] [Related]  

  • 7. The poly (ADP ribose) polymerase inhibitor niraparib: Management of toxicities.
    Moore KN; Mirza MR; Matulonis UA
    Gynecol Oncol; 2018 Apr; 149(1):214-220. PubMed ID: 29397193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world adverse events with niraparib 200 mg/day maintenance therapy in ovarian cancer: a retrospective study.
    Gallagher JR; Heap KJ; Carroll S; Travers K; Harrow B; Westin SN
    Future Oncol; 2019 Dec; 15(36):4197-4206. PubMed ID: 31707856
    [No Abstract]   [Full Text] [Related]  

  • 9. Niraparib: First Global Approval.
    Scott LJ
    Drugs; 2017 Jun; 77(9):1029-1034. PubMed ID: 28474297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Budget impact of niraparib as maintenance treatment in recurrent ovarian cancer following platinum-based chemotherapy.
    Neeser K; O'Neil WM; Stern L; Harrow B; Travers K
    J Comp Eff Res; 2019 Jun; 8(8):577-587. PubMed ID: 30935213
    [No Abstract]   [Full Text] [Related]  

  • 11. Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial.
    Oza AM; Matulonis UA; Malander S; Hudgens S; Sehouli J; Del Campo JM; Berton-Rigaud D; Banerjee S; Scambia G; Berek JS; Lund B; Tinker AV; Hilpert F; Vázquez IP; D'Hondt V; Benigno B; Provencher D; Buscema J; Agarwal S; Mirza MR
    Lancet Oncol; 2018 Aug; 19(8):1117-1125. PubMed ID: 30026000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic drug evaluation of niraparib for the treatment of ovarian cancer.
    Longoria TC; Tewari KS
    Expert Opin Drug Metab Toxicol; 2018 May; 14(5):543-550. PubMed ID: 29620474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of niraparib on cardiac repolarization in patients with platinum-sensitive, recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer.
    Moore K; Chan JK; Secord AA; Patel MR; Callahan T; Guo W; Zhang ZY
    Cancer Chemother Pharmacol; 2019 Apr; 83(4):717-726. PubMed ID: 30680521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of Maintenance Therapy Based on Molecular Classification Following Treatment of Primary Epithelial Ovarian Cancer in the United States.
    Penn CA; Wong MS; Walsh CS
    JAMA Netw Open; 2020 Dec; 3(12):e2028620. PubMed ID: 33295974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial.
    Mirza MR; Åvall Lundqvist E; Birrer MJ; dePont Christensen R; Nyvang GB; Malander S; Anttila M; Werner TL; Lund B; Lindahl G; Hietanen S; Peen U; Dimoula M; Roed H; Ør Knudsen A; Staff S; Krog Vistisen A; Bjørge L; Mäenpää JU;
    Lancet Oncol; 2019 Oct; 20(10):1409-1419. PubMed ID: 31474354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world outcomes of niraparib treatment in patients with ovarian cancer: a multicenter non-interventional study in China.
    Li J; Yang J; Shou H; Zhang L; Huang X; Tang X; Zheng F; Liu F; Wen H; Yang H; Wang H; Li Z; Chen X; Ju X; Cheng X; Tang J; Zhang M; Wu X
    Cancer Commun (Lond); 2023 Jun; 43(6):716-719. PubMed ID: 37040265
    [No Abstract]   [Full Text] [Related]  

  • 17. A phase I study of the PARP inhibitor niraparib in combination with bevacizumab in platinum-sensitive epithelial ovarian cancer: NSGO AVANOVA1/ENGOT-OV24.
    Mirza MR; Bergmann TK; Mau-Sørensen M; Christensen RD; Åvall-Lundqvist E; Birrer MJ; Jørgensen M; Roed H; Malander S; Nielsen F; Lassen U; Brøsen K; Bjørge L; Mäenpää J
    Cancer Chemother Pharmacol; 2019 Oct; 84(4):791-798. PubMed ID: 31375879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fighting against the challenge of treating patients with late-line ovarian cancer: are we there yet?
    Marchetti C; Fagotti A; Scambia G
    Lancet Oncol; 2019 May; 20(5):603-605. PubMed ID: 30948274
    [No Abstract]   [Full Text] [Related]  

  • 19. The role of niraparib for the treatment of ovarian cancer.
    Ethier JL; Lheureux S; Oza AM
    Future Oncol; 2018 Oct; 14(25):2565-2577. PubMed ID: 29856239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Budget impact analysis of niraparib and olaparib for maintenance treatment of platinum-sensitive, recurrent ovarian cancer in the US.
    Wu L; Zhong L
    J Med Econ; 2019 Feb; 22(2):187-195. PubMed ID: 30522378
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.